https://www.selleckchem.com/pr....oducts/Erlotinib-Hyd
mpared with vaginal brachytherapy alone (five studies (n=463); OR 0.78 (95% CI 0.34 to 1.8; I2=48%). CONCLUSIONS External beam radiotherapy with or without vaginal brachytherapy decreased the locoregional recurrence threefold for stage II endometrial cancer, regardless of pelvic lymph node assessment. Most women who suffered recurrence locoregionally had a least one high risk factor. Vaginal brachytherapy alone may be sufficient therapy for node negative stage II endometrial cancer without uterine risk factors, while t
Like
Comment
Share
